You have 9 free searches left this month | for more free features.

tivantinib

Showing 1 - 25 of 30

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Colorectal Cancer Metastatic, C-met Overexpression Trial in Rozzano (Tivantinib (ARQ197))

Completed
  • Colorectal Cancer Metastatic
  • C-met Overexpression
  • Tivantinib (ARQ197)
  • Rozzano, Milano, Italy
    Istituto Clinico Humanitas
Sep 8, 2022

Advanced Solid Tumors Trial (Tivantinib, Anti-Cancer Combination Therapy)

Completed
  • Advanced Solid Tumors
  • Tivantinib
  • Anti-Cancer Combination Therapy
  • (no location specified)
Feb 17, 2021

Malignant Pleural Mesothelioma, Nonsquamous Nonsmall Cell Tumor of Lung Trial in Rozzano (Tivantinib)

Completed
  • Malignant Pleural Mesothelioma
  • Nonsquamous Nonsmall Cell Neoplasm of Lung
  • Tivantinib
  • Rozzano, Milan, Italy
    Istituto Clinico Humanitas
Jan 20, 2021

Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas) Trial in France, United Kingdom, United States (Tivantinib (ARQ 197))

Terminated
  • Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)
  • Tivantinib (ARQ 197)
  • Los Angeles, California
  • +9 more
Mar 12, 2021

Sarcoma, Stomach Tumors, Tumors Trial run by the NCI (Pazopanib, ARQ 197)

Completed
  • Sarcoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Jun 23, 2021

Hepatocellular Carcinoma Trial in Worldwide (Tivantinib, Placebo)

Completed
  • Hepatocellular Carcinoma
  • Tivantinib
  • Placebo
  • Tucson, Arizona
  • +112 more
Mar 12, 2021

Metastatic Colorectal Cancer Trial in Worldwide (Tivantinib, Placebo, Cetuximab)

Completed
  • Metastatic Colorectal Cancer
  • Tivantinib
  • +3 more
  • Beverly Hills, California
  • +39 more
Mar 12, 2021

Refractory Multiple Myeloma Trial in Houston (drug, other, procedure)

Completed
  • Refractory Multiple Myeloma
  • Tivantinib
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2019

Non Squamous, Non-small-cell Lung Cancer Trial in Worldwide (Tivantinib, Placebo, Erlotinib)

Terminated
  • Non Squamous, Non-small-cell Lung Cancer
  • Tivantinib
  • +2 more
  • Tucson, Arizona
  • +304 more
Mar 12, 2021

Hepatic Impairment, Solid Tumor, Cancer Trial in Los Angeles, Hackensack (Tivantinib)

Completed
  • Hepatic Impairment
  • +2 more
  • Tivantinib
  • Los Angeles, California
  • +1 more
Feb 8, 2019

Solid Tumors Trial in San Antonio (Tivantinib, Placebo)

Completed
  • Solid Tumors
  • Tivantinib
  • Placebo
  • San Antonio, Texas
    START - South Texas Accelerated Research Therapeutics, LLC
Feb 8, 2019

Solid Tumors Trial in San Antonio (tivantinib, omeprazole, s-warfarin)

Completed
  • Solid Tumors
  • tivantinib
  • +6 more
  • San Antonio, Texas
    START - South Texas Accelerated Research Therapeutics, LLC
Feb 8, 2019

Solid Tumors Trial in United States (Tivantinib (ARQ 197) Capsule, Tivantinib (ARQ 197) Tablet, Tivantinib (ARQ 197) Capsule D,

Completed
  • Solid Tumors
  • Tivantinib (ARQ 197) Capsule
  • +2 more
  • Santa Monica, California
  • +3 more
Feb 8, 2019

Cancer Target Therapy Efficacy

Active, not recruiting
  • Cancer
  • RNA sequencing
  • +5 more
  • Walnut, California
  • +6 more
Sep 13, 2021

Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma Trial in United States (Laboratory

Completed
  • Hormone-Resistant Prostate Cancer
  • +3 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Washington, District of Columbia
  • +19 more
Aug 13, 2018

Metastatic NSCLC Trial in United States (ARQ 197 plus erlotinib, Pemetrexed, docetaxel or gemcitabine)

Completed
  • Metastatic Non-Small Cell Lung Cancer
  • ARQ 197 plus erlotinib
  • Pemetrexed, docetaxel or gemcitabine
  • Stanford, California
  • +12 more
Mar 5, 2018

Adult Solid Tumor Trial in United States (other, biological, drug)

Completed
  • Adult Solid Neoplasm
  • Laboratory Biomarker Analysis
  • +4 more
  • Duarte, California
  • +6 more
Apr 2, 2018

Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in United States (Erlotinib

Completed
  • Recurrent Renal Cell Carcinoma
  • +4 more
  • Erlotinib Hydrochloride
  • +2 more
  • Tucson, Arizona
  • +213 more
Dec 12, 2018

Solid Tumor Trial in Hershey, Pittsburgh (biological, other, drug)

Completed
  • Solid Neoplasm
  • Bevacizumab
  • +3 more
  • Hershey, Pennsylvania
  • +1 more
Oct 11, 2017

Carcinoma, Small Cell Trial in Padova (ARQ197)

Terminated
  • Carcinoma, Small Cell
  • Padova, Italy
    Istituto Oncologico Veneto
Jun 9, 2017

Advanced Hepatocellular Carcinoma Trial in Kashiwa-city (ARQ 197)

Completed
  • Advanced Hepatocellular Carcinoma
  • ARQ 197
  • Kashiwa-city, Chiba, Japan
    (unnamed)
Feb 28, 2017

Malignant Solid Tumour, Gastroesophageal Cancer Trial in United States (Tivantinib, FOLFOX)

Completed
  • Malignant Solid Tumour
  • Gastroesophageal Cancer
  • New Haven, Connecticut
  • +8 more
Oct 3, 2016

Epithelioid Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma Trial in United States (Laboratory

Terminated
  • Epithelioid Mesothelioma
  • +5 more
  • Laboratory Biomarker Analysis
  • Tivantinib
  • Duarte, California
  • +17 more
Aug 26, 2016

Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative Trial in Boston (Laboratory Biomarker Analysis,

Completed
  • Estrogen Receptor Negative
  • +5 more
  • Laboratory Biomarker Analysis
  • Tivantinib
  • Boston, Massachusetts
  • +1 more
Feb 23, 2016

Non-small-cell Lung Cancer Trial in Osaka, Shizuoka (ARQ 197 and Erlotinib)

Completed
  • Non-small-cell Lung Cancer
  • ARQ 197 and Erlotinib
  • Osaka, Japan
  • +1 more
Mar 14, 2017